SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Canntab Therapeutics Limited (CTABF) .
本页证实的标准:
- VALUE (0/100, 未通过) — 综合估值评分低于60/100的通过门槛。
SharesGrow 综合评分： 5/100 其中 0/7 项标准通过。
SharesGrow 7-Criteria Score
✗
健康
0/100
Debt-to-Equity & liquidity
→ Health
估值概览 — CTABF
估值倍数
P/E (TTM)0.0
前瞻 P/EN/A
PEG 比率N/A
前瞻 PEGN/A
P/B 比率0.00
P/S 比率0.01
EV/EBITDA0.0
每股数据
EPS (TTM)$-0.10
每股账面价值$0.00
每股营收$0.01
每股自由现金流$0.00
收益率与内在价值
盈利收益率N/A
股息收益率0.00%
P/E Ratio & Earnings Yield
每股收益 (EPS) 历史
| Year |
EPS（稀释） |
营收 |
净利润 |
净利润率 |
| 2013 |
$-8.30 |
$0.00 |
$-1.56M |
- |
| 2014 |
$-1.53 |
$0.00 |
$-301.24K |
- |
| 2015 |
$-1.18 |
$0.00 |
$-178.53K |
- |
| 2016 |
$-0.75 |
$0.00 |
$-173.84K |
- |
| 2017 |
$-0.07 |
$0.00 |
$-1.12M |
- |
| 2018 |
$-0.11 |
$26.67K |
$-2.41M |
-9031.4% |
| 2019 |
$-0.10 |
$240K |
$-2.46M |
-1024.4% |
| 2020 |
$-0.10 |
$133.33K |
$-2.61M |
-1955.4% |
| 2021 |
$-0.13 |
$0.00 |
$-4.42M |
- |
| 2022 |
$-0.10 |
$293.36K |
$-3.69M |
-1257.6% |
